Does EPCORITAMAB-BYSP Cause Malignant neoplasm progression? 24 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Malignant neoplasm progression have been filed in association with EPCORITAMAB-BYSP. This represents 2.5% of all adverse event reports for EPCORITAMAB-BYSP.
24
Reports of Malignant neoplasm progression with EPCORITAMAB-BYSP
2.5%
of all EPCORITAMAB-BYSP reports
10
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From EPCORITAMAB-BYSP?
Of the 24 reports, 10 (41.7%) resulted in death, 1 (4.2%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EPCORITAMAB-BYSP. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does EPCORITAMAB-BYSP Cause?
Cytokine release syndrome (369)
Diffuse large b-cell lymphoma (206)
Diffuse large b-cell lymphoma refractory (198)
Pyrexia (79)
Immune effector cell-associated neurotoxicity syndrome (77)
Covid-19 (39)
Neutrophil count decreased (35)
Hypogammaglobulinaemia (32)
Platelet count decreased (32)
Cytomegalovirus infection (31)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which EPCORITAMAB-BYSP Alternatives Have Lower Malignant neoplasm progression Risk?
EPCORITAMAB-BYSP vs EPERISONE
EPCORITAMAB-BYSP vs EPHEDRINE
EPCORITAMAB-BYSP vs EPINASTINE
EPCORITAMAB-BYSP vs EPINEPHRINE
EPCORITAMAB-BYSP vs EPINEPHRINE\LIDOCAINE